The development of trastuzumab, the first HER2-directed monoclonal antibody, greatly improved the prognosis and outcomes of patients with HER2-positive breast cancer, but management remains challenging in the post-trastuzumab era [5]. Here, ERBB2 is linked to breast carcinoma.